Solutions
Modelling and Simulation
Mechanism of Action Modelling
Exposure Response Modelling
Translational Modelling
Tumour Growth Inhibition Modelling
Population PK and NCA
PBPK Modelling
Clinical Trial Simulation
Biostatistics
Data Science & Bioinformatics
Virtual Tumour
Precision Oncology
Resources
Scientific Content
Investor Content
FAQs
News
All News
Investor News / RNS
Blog
Events
AIM Rule 26
Share Information
Investor News / RNS
Board of Directors
Advisors
Corporate Governance
Financial Reports
Corporate Documents
Registration
About Us
Partners
Team
Careers
Contact
Solutions
Modelling and Simulation
Mechanism of Action Modelling
Exposure Response Modelling
Translational Modelling
Tumour Growth Inhibition Modelling
Population PK and NCA
PBPK Modelling
Clinical Trial Simulation
Biostatistics
Data Science & Bioinformatics
Virtual Tumour
Precision Oncology
Resources
Scientific Content
Investor Content
FAQs
News
All News
Investor News / RNS
Blog
Events
AIM Rule 26
Share Information
Investor News / RNS
Board of Directors
Advisors
Corporate Governance
Financial Reports
Corporate Documents
Registration
About Us
Partners
Team
Careers
Contact
Solutions
Modelling and Simulation
Mechanism of Action Modelling
Exposure Response Modelling
Translational Modelling
Tumour Growth Inhibition Modelling
Population PK and NCA
PBPK Modelling
Clinical Trial Simulation
Biostatistics
Data Science & Bioinformatics
Virtual Tumour
Precision Oncology
Resources
Scientific Content
Investor Content
FAQs
News
All News
Investor News / RNS
Blog
Events
AIM Rule 26
Share Information
Investor News / RNS
Board of Directors
Advisors
Corporate Governance
Financial Reports
Corporate Documents
Registration
About Us
Partners
Team
Careers
Contact
30th September 2021 – Slide presentation of results for year ended 30 June 2021
30th September 2021 – Slide presentation of results for year ended 30 June 2021
Dr Jim Millen, CEO
Physiomics Update – 30 Sept 2021
Date
30th September 2021
Category
Investor
